Skip to main content
SpringWorks gains $162M from IPO launch

The launch of SpringWorks Therapeutics' initial public offering Friday raised $162 million after the company sold 9 million shares at $18 per share, with the funds to be used to support research for products in its development pipeline. SpringWorks' most advanced candidate is nirogacestat, a cancer treatment for desmoid tumors that is being evaluated in a late-stage trial, with preliminary data from this trial expected to become available in 2021.

Full Story: